SCHEMBL7096747

SCHEMBL7096747

CCCCOC(=O)N1CCC(C(C)=O)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.58
LMNA P02545 2/20 0.58
POLB P06746 1/20 0.58
GAA P10253 1/20 0.53
CHRM1 P11229 2/20 0.46
CHRM2 P08172 1/20 0.45
ALDH1A1 P00352 5/20 0.44
NOS3 P29474 1/20 0.43
NOS2 P35228 1/20 0.43
PKM P14618 1/20 0.43
MAPT P10636 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
THRB P10828 1/20 0.42
ATM Q13315 1/20 0.42
HTT P42858 1/20 0.41
HRH2 P25021 1/20 0.41
HRH1 P35367 1/20 0.41
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL355693 0.87 SMN1; SMN2 (0.58) SMN1; SMN2LMNAPOLBGAACHRM1
SCHEMBL3664936 0.87 LMNA (0.58) SMN1; SMN2LMNAPOLBGAACHRM1
SCHEMBL5823241 0.86 GAA (0.73) SMN1; SMN2LMNAPOLBGAACHRM1
SCHEMBL7449135 0.85 POLB (0.63) SMN1; SMN2LMNAPOLBGAACHRM1
SCHEMBL12436957 0.84 GAA (0.71) SMN1; SMN2LMNAPOLBGAACHRM1
SCHEMBL16102147 0.84 GAA (0.56) SMN1; SMN2LMNAPOLBGAACHRM1
SCHEMBL12615399 0.84 MAPT (0.59) SMN1; SMN2LMNAPOLBGAACHRM1
SCHEMBL5158334 0.83 LMNA (0.53) SMN1; SMN2LMNAPOLBGAAALDH1A1
SCHEMBL7339506 0.83 LMNA (0.61) SMN1; SMN2LMNAPOLBGAACHRM1
SCHEMBL184778 0.83 LMNA (0.61) SMN1; SMN2LMNAPOLBGAACHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025149628-A1 PIPERIDINE DERIVATIVES AS INHIBITORS OF NICOTINAMIDE N-METHYL TRANSFERASE ASTRAZENECA AB (SE) 2025-07-17 WO disclosed
US-7928098-B2 Therapeutic and/or preventive agents for a sleep disorder KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-04-19 US disclosed
US-7880013-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-01 US disclosed
US-20100256361-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-06-17 US disclosed
US-7718808-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-05-18 US disclosed
EP-1326619-A2 PYRROLIDINE MODULATORS OF CCR5 CHEMOKINE RECEPTOR ACTIVITY Merck & Co., Inc. (US) 2003-07-16 EP disclosed
WO-2002034716-A2 PYRROLIDINE MODULATORS OF CCR5 CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2002-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256361-A1 THIAZOLE DERIVATIVES ADORA2A, ADORA3, ADORA1 SMN1; SMN2 4865/4885LMNA 3679/4885POLB 4509/4885
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER HCRTR1, MTNR1A, HCRTR2 SMN1; SMN2 3229/4885LMNA 3303/4885POLB 3885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.